Galway-based MedTech company Neurent Medical has secured €62.5 million ($74 million) in an oversubscribed Series C funding round to accelerate commercial growth, expand clinical evidence and advance its product and indication pipeline.
The round was led by MVM Partners, with significant participation from Sofinnova Partners. Existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland also continued their support.
Founded in 2015, Neurent Medical develops minimally invasive treatments for chronic inflammatory sino-nasal diseases, with a focus on chronic rhinitis.
Advancing A Minimally Invasive Solution
At the center of Neurent’s portfolio is the NEUROMARK System, which uses proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves. These nerves are a key driver of chronic rhinitis symptoms.
The in-office procedure is designed to provide long-lasting symptom relief with minimal downtime and a strong safety profile. Rather than simply addressing symptoms, the system targets the underlying nerve activity associated with persistent inflammation.
Chronic rhinitis affects millions of people globally and is characterized by ongoing nasal congestion, runny nose, sneezing and postnasal drip, often significantly impacting quality of life.
“This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most,” said Brian Shields, CEO of Neurent Medical. “We are pleased to welcome MVM Partners and Sofinnova Partners, two global leaders in MedTech investing, to our team.”
Advertisement
Strengthening Commercial And Clinical Momentum
The newly raised capital will be used to scale commercial operations, generate further clinical data and expand the company’s pipeline into additional indications.
As part of the financing, Kyle Dempsey, Partner at MVM Partners, and Cedric Moreau, Partner at Sofinnova Partners, have joined Neurent Medical’s Board of Directors.
“Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief,” said Kyle Dempsey. “Neurent has established a new benchmark in this fast-growing category with a proprietary impedance control system that delivers real-time feedback, giving clinicians greater control and predictability during procedures.”
About Neurent Medical
Founded in 2015 and headquartered in Galway, Ireland, Neurent Medical develops innovative treatments for chronic inflammatory sino-nasal diseases. Its NEUROMARK System offers a minimally invasive, in-office procedure that targets hyperactive posterior nasal nerves to reduce persistent rhinitis symptoms and improve patient quality of life.
